Haleon plc (LON:HLN), a leading consumer health company, has witnessed a significant improvement in its Return on Capital Employed (ROCE) over the past four years. This growth can be attributed to two key factors: improved operational efficiency and a strong focus on innovation.



Improved Operational Efficiency

Haleon has demonstrated a remarkable ability to generate higher profits from its existing capital base. This is evident in the company's operating margin, which has increased from 21.85% in 2020 to 22.15% in 2024. This improvement suggests that Haleon has become more efficient in its operations, leading to higher returns on the capital it has invested. The company's disciplined capital allocation strategy, which involves divesting non-core brands and reinvesting in core businesses and strategic initiatives, has played a significant role in driving this operational efficiency.



Innovation and Strong Brand Portfolio

Haleon's brand portfolio, including Sensodyne, Polident, Parodontax, and Biotene, has driven market share gains and contributed to the company's growth. The company's focus on innovation and strong brand execution has led to organic revenue growth, which in turn has contributed to the increase in ROCE. For instance, Haleon's Power Brands, including Sensodyne, parodontax, Advil, and Theraflu, have shown organic growth of 5.4% in Q3 2024, reflecting the strength of the portfolio and the company's ability to innovate and adapt to market demands.



In conclusion, Haleon's ROCE growth can be attributed to its improved operational efficiency and strong focus on innovation. The company's disciplined capital allocation strategy, coupled with its commitment to investing in core businesses and strategic initiatives, has enabled it to drive higher returns on its capital employed. As Haleon continues to focus on these key factors, investors can expect the company to maintain its strong performance and continue to drive growth in the consumer health sector.